You are here

Novel Pharmaceutical Solvent-Water Separation System

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44GM071093-02
Agency Tracking Number: GM071093
Amount: $408,674.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: 2007
Award Year: 2007
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
COMPACT MEMBRANE SYSTEMS, INC. 335 WATER STREET
NEWPORT, DE 19804
United States
DUNS: 808898894
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 STUART NEMSER
 (302) 999-7996
 stuart.nemser@compactmembrane.com
Business Contact
 LOUIS DINETTA
Phone: (302) 999-7996
Email: ldinetta@compactmembrane.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): In Phase I we exceeded all key objectives. We demonstrated in both pervaporation and vapor separation the combination of high membrane permeation and high membrane separation when evaluating isopropyl alcohol (IPA)-Water separation. Membrane stability, which had been concern of reviewers, was shown to be excellent and far superior to other commercial membranes. CMS membranes were shown to be stable up to 130'C and over the whole compositional operating range. Economic evaluations showed the CMS membranes to have in excess of 80% capital savings compared to existing drying processes. In addition to work on IPA-water, two other pharmaceutical solvents were successfully evaluated. Leaching studies have shown the CMS membranes to be stable. Based on results and commercialization analysis the CMS system is seen as a platform technology. Significant opportunities exist in pharmaceutical solvent recovery enhancing chemical reactions, chemical industry solvent recovery, manufacture of fuel grade ethanol and stabilizing industrial esters. With many opportunities, a large number of industrial and pharmaceutical companies as well as leading researchers have committed to actively participate in this program. This participation will enhance overall chances for commercialization. In Phase II we will first fabricate high flux composite membrane modules. Then we would focus our demonstration on IPA-water systems operating in pervaporation (PV) mode. Focus will be on PV since this is the simplest system for the end user. Once successful basic data on IPA-water in PV is obtained we will expand the evaluation to other pharmaceutical solvents and also evaluating membranes in the vapor separation mode. Additional upgrades will include modeling and system design to enhance overall purification; long term testing plus extended solvent leaching tests; develop enhanced membrane modules using commercial hollow fiber supports; building large skid for field testing and expanding our economic evaluation to show superior performance to alternative drying routes. Throughout this Phase II we will work closely with our industrial partners. This program develops a low cost, simple, process to recover pharmaceutical solvents. This will encourage solvent reuse which is environmentally attractive and cost effective. The process will also keep potential biological contaminants out of the environment.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government